A new estimate: some weight loss may persist after stopping
A new analysis suggests that people who stop taking Ozempic-like medications keep off roughly 25% of the weight they lost for up to a year after stopping. The bigger headline, however, is what researchers say they still cannot answer: how much of the regained weight is fat versus lean mass like muscle.
That uncertainty matters because early research has indicated that 40% to 60% of the weight lost during treatment with GLP-1 and related medications may come from lean muscle mass. If weight returns mostly as fat, a person’s fat-to-lean ratio could worsen compared with where they started, which may carry health consequences.
Why GLP-1 drugs work, and why many people stop
GLP-1 medications such as semaglutide (often associated with Ozempic or Wegovy), tirzepatide, and others are prescribed to help manage type 2 diabetes or body weight. They mimic a natural hormone called glucagon-like peptide-1 (GLP-1), which helps control blood sugar and can reduce appetite by helping people feel full sooner.
But the analysis notes that many patients discontinue these drugs within a year, often due to side effects (including gastrointestinal issues), cost, or prescription access complications. When treatment ends, appetite suppression can fade quickly, which may contribute to rapid regain.
What the review actually measured
To understand weight regain after stopping therapy, researchers examined 48 studies and found major inconsistencies: short follow-up windows, different timing of check-ins, and uneven quality. To reduce noise, they narrowed their review to six randomized controlled trials totaling more than 3,200 participants. Each trial included at least one follow-up at 12 weeks or later after stopping medication, and participants had lost at least 3 kilograms during treatment.
Across those six trials, the pooled pattern was consistent: fast regain early, then a gradual slowing. By 52 weeks after stopping, participants regained about 60% of the weight they had lost while on treatment.
What happens after a year, and the unanswered body composition question
The researchers then modeled what might happen beyond one year. Their projection suggests regain may begin to plateau around 60 weeks, potentially tapering after people regain roughly 75% of the lost weight. Why a plateau might occur is not settled. Possible explanations include lasting changes in eating habits, or physiological changes related to hormones and brain appetite pathways.
Still, the most important unknown remains body composition. If a meaningful portion of initial weight loss was lean mass, it is unclear whether lean mass returns at the same rate as fat after the medication stops. The authors note that newer, more effective GLP-1 related drugs can produce larger overall weight reductions, but may not necessarily preserve lean mass better.
What this could mean for long-term weight management
The authors suggest that weight management after stopping GLP-1 therapy should be treated as a key part of care, not an afterthought. They point to strategies that may help, including support for diet quality and regular exercise, which can be especially relevant for preserving or rebuilding muscle.
They also note that clinicians may consider tapering strategies in some cases, as a possible way to reduce abrupt rebound, though the best approach can depend on an individual’s situation and requires medical supervision.